Evidence map›Paper›PMID 41473820›Full record

ArticleCase reports in oncological medicine2025

Hypertriglyceridemia-Induced Acute Pancreatitis Associated with Ruxolitinib for Hemophagocytic Lymphohistiocytosis: A Case Report.

Sarah Medina, Leslie A Ynalvez, Hyeon-Ju Ryoo Ali, Maria E Cabanillas, Ihab Hamzeh, Salil Kumar, Nicolas Palaskas, Anita Deswal, Shaden Khalaf

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Case reports in oncological medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Sarah MedinaDepartment of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA, mdanderson.org.ORCID https://orcid.org/0009-0004-9778-6798
Leslie A YnalvezDepartment of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA, mdanderson.org.
Hyeon-Ju Ryoo AliDepartment of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA, mdanderson.org.
Maria E CabanillasDepartment of Endocrine Neoplasia and Hormonal Disorders, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA, mdanderson.org.
Ihab HamzehDepartment of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA, mdanderson.org.
Salil KumarDepartment of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA, mdanderson.org.
Nicolas PalaskasDepartment of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA, mdanderson.org.
Anita DeswalDepartment of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA, mdanderson.org.
Shaden KhalafDepartment of Cardiology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA, mdanderson.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ruxolitinib is a Janus kinase inhibitor that has been associated with lipid abnormalities, including a 15% incidence of hypertriglyceridemia. We describe a case of a 37-year-old man with refractory T-cell lymphoma treated with ruxolitinib for hemophagocytic lymphohistiocytosis (HLH). Following ruxolitinib use, the patient developed severe epigastric abdominal pain with elevated amylase, lipase, and triglycerides. This led to a suspicion of hypertriglyceridemia-induced pancreatitis requiring an insulin infusion. Unfortunately, the patient experienced multiorgan failure and expired. While ruxolitinib has been associated with hypertriglyceridemia, severe lipid abnormalities, as observed in this case, are rare. Furthermore, assessing the incidence of severe hypertriglyceridemia in the setting of HLH is challenging, given that the disease itself contributes to elevated triglyceride levels. This case highlights the need for a more vigilant approach in monitoring lipid parameters when using ruxolitinib for HLH treatment, especially among patients with concomitant risk factors.

Indexed as

hyperlipidemiahypertriglyceridemiaJakafipancreatitisruxolitinibtriglycerides

Identifiers

PMID41473820
PMCPMC12747063

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.